Editor's Pick

The US Federal Trade Commission's recent challenge raises the question who Illumina can acquire while remaining a quasi-monopolist for sequencing equipment.

Although the logistics still need to be worked out, the partners hope to streamline oncologists' experience ordering tests that can inform patient care.

The firm will build liquid biopsy companion diagnostic tests that complement its tissue-based assays and are tailored for drugs developed by pharma partners.

The firms will present a clinical comparison study using the workflow to detect FGFR mutations in 50 urothelial cancer patients later this year.

With $1.2 billion in funding earmarked for more than 40 projects, the portfolio represents a path out of the SARS-CoV-2 pandemic for the US.

The firm expects to increase commercial coverage for its pigmented lesion assay for melanoma while widening its pipeline to diagnose other varieties of skin cancer.

The firm is also developing an instrument-free molecular diagnostic assay technology for the home testing market.

The firm will consolidate its businesses in newly-built headquarters in Fort Myers, Florida, which it plans to occupy around September.